Sionna Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SIONNA THERAPEUTICS, INC. | ||
| By: | /s/ | Michael Cloonan |
| Name: | Michael Cloonan, M.B.A. | |
| Title: | President and Chief Executive Officer | |
POWER OF ATTORNEY AND SIGNATURES
Each individual whose signature appears below hereby constitutes and appoints Michael Cloonan, M.B.A., and Elena Ridloff, C.F.A., as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report and Power of Attorney has been signed by the following person in the capacities and on the date indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Michael Cloonan | President, Chief Executive Officer and Director (Principal Executive Officer) | March 2, 2026 |
| Michael Cloonan, M.B.A. | ||
| /s/ Elena Ridloff | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | March 2, 2026 |
| Elena Ridloff, C.F.A. | ||
| /s/ Paul Clancy | Chair of the Board of Directors | March 2, 2026 |
| Paul Clancy, M.B.A. | ||
| /s/ Bruce Booth | Director | March 2, 2026 |
| Bruce Booth, D.Phil. | ||
| /s/ H. Edward Fleming, Jr. | Director | March 2, 2026 |
| H. Edward Fleming, Jr., M.D. | ||
| /s/ Lucian Iancovici | Director | March 2, 2026 |
| Lucian Iancovici, M.D. | ||
| /s/ Joshua Resnick | Director | March 2, 2026 |
| Joshua Resnick, M.D., M.B.A. | ||
| Signature | Title | Date |
|---|---|---|
| /s/ Marcella K. Ruddy | Director | March 2, 2026 |
| Marcella K. Ruddy, M.D. | ||
| /s/ Laurie Stelzer | Director | March 2, 2026 |
| Laurie Stelzer, M.B.A. | ||
| /s/ Peter A. Thompson | Director | March 2, 2026 |
| Peter A. Thompson, M.D. | ||
| /s/ Joanne Viney | Director | March 2, 2026 |
| Joanne Viney, Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.